• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: U.S. specialty pharma's M&A focus shifts to pipelines and innovative products

Report: U.S. specialty pharma's M&A focus shifts to pipelines and innovative products

June 14, 2016
CenterWatch Staff

Despite the ongoing challenges weighing on the U.S. specialty pharmaceutical sector, companies will steadily resume M&A with a more refined focus, said Moody's Investors Service. The ratings agency said it expects acquisitive specialty companies will increase their focus on products with unmet medical need, companies with pipeline drugs and those providing geographic expansion.

In a new report entitled, "U.S. Pharmaceuticals—Specialty Pharma: After Turmoil, M&A Will Steadily Resume but with a Shift in Focus," Moody's noted that operating challenges, dented equity valuations, and reduced access to the credit markets are making it more difficult for specialty pharmaceutical companies to continue to make large acquisitions. Moody's analysts said that the slowdown in acquisitions, along with the scrutiny on aggressive price increases, will force many specialty pharmaceutical companies to shift their growth strategies.

"In the specialty pharmaceutical space, we expect companies will be moving away from acquisitions that rely on price increases or substantial cost reductions to drive value," said Moody's Senior Vice President Michael Levesque. "To restore investor confidence, companies will seek products that have sustainable volume growth, driving more long-term value through innovative product development focusing on areas of unmet medical need and using less aggressive capital structures."

Compared to large, traditional, R&D-based pharmaceutical companies, specialty pharmaceutical companies are smaller companies with more limited breadth. In recent years, specialty pharmaceutical companies have typically relied on acquisitions for growth, rather than heavy investment in R&D. In some cases, acquisitions were followed by large price increases.

Moody's noted that within the sector, companies like Valeant Pharmaceuticals International (B2 negative) and Concordia Healthcare (B3 stable) —both of which more aggressively pursued some combination of rapid acquisitions, high drug price increases and high financial leverage—now face the biggest challenges.

Additionally, the report noted that the pace of the shift in business strategies would differ across the sector depending on factors including financial leverage. Some, like Valeant, will not be making acquisitions for the foreseeable future, according to Moody's.

"Shifts have execution risks, particularly as companies deal with the challenges at hand, including lower prices on acquired products and government investigations," said Levesque. "But, for the time being, there are quite a few companies—namely Valeant, Endo and Concordia—that are in deleveraging mode, which will give them time to reassess their strategies and long-range plans."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing